Virus reactivation had no influence on the classification factor
SampleID . | PatID . | Virus . | Days/HSCT . | aGvHD development . | CF . |
---|---|---|---|---|---|
14292 | 2225 | CMV | 32 | NA | −0.773 |
14283 | 2225 | CMV | 180 | NA | −0.498 |
14378 | 2401 | CMV | 14 | NA | 0.751 |
14375 | 2401 | CMV | 62 | NA | −0.434 |
15751 | 2401 | CMV | 80 | NA | 0.049 |
14412 | 2715 | CMV | 125 | 38 | −1.1 |
14441 | 2718 | CMV | 43 | NA | 0.247 |
14465 | 2725 | CMV | 62 | 25 | −0.297 |
14575 | 2890 | CMV | 34 | 15 | −0.557 |
14642 | 3023 | CMV | 47 | NA | 0.190 |
14640 | 3023 | CMV | 54 | NA | −0.238 |
15278 | 3203 | CMV | 47 | 32 | −0.326 |
15488 | 3203 | CMV | 60 | 32 | −0.338 |
17182 | 3203 | CMV | 95 | 32 | 0.107 |
17183 | 3203 | CMV | 122 | 32 | −0.758 |
16629 | 3203 | CMV | 129 | 32 | −0.33 |
16630 | 3203 | CMV | 136 | 32 | −0.328 |
16628 | 3203 | CMV | 143 | 32 | −0.69 |
17184 | 3203 | CMV | 150 | 32 | −0.474 |
14753 | 3263 | CMV | −1 | 53 | 0.728 |
14751 | 3263 | CMV | 19 | 53 | 0.657 |
15452 | 3340 | CMV | 53 | 34 | 0.676 |
17149 | 2038 | EBV | 357 | NA | −0.133 |
15486 | 2250 | EBV | 303 | NA | −0.443 |
15718 | 2250 | EBV | 331 | NA | −0.724 |
14447 | 2719 | EBV | 120 | 48 | −1.266 |
17173 | 2890 | EBV | 248 | 15 | −0.887 |
15719 | 3049 | EBV | 159 | 29 | 0.555 |
17174 | 3049 | EBV | 166 | 29 | −0.009 |
17175 | 3049 | EBV | 173 | 29 | −0.034 |
16125 | 3049 | EBV | 179 | 29 | 0.319 |
17176 | 3049 | EBV | 186 | 29 | 0.365 |
16625 | 3049 | EBV | 200 | 29 | −0.044 |
17177 | 3049 | EBV | 214 | 29 | 0.056 |
14673 | 3052 | EBV | 32 | NA | −0.074 |
14687 | 3065 | EBV | 31 | 52 | 0.558 |
15450 | 3264 | EBV | 59 | NA | −0.763 |
16360 | 3264 | EBV | 94 | NA | −0.674 |
15490 | 3340 | EBV | 46 | 34 | 0.952 |
15721 | 3340 | EBV | 74 | 34 | −0.725 |
15787 | 3340 | EBV | 81 | 34 | −0.577 |
17186 | 3340 | EBV | 136 | 34 | −0.573 |
15491 | 3341 | EBV | 34 | NA | −0.3 |
SampleID . | PatID . | Virus . | Days/HSCT . | aGvHD development . | CF . |
---|---|---|---|---|---|
14292 | 2225 | CMV | 32 | NA | −0.773 |
14283 | 2225 | CMV | 180 | NA | −0.498 |
14378 | 2401 | CMV | 14 | NA | 0.751 |
14375 | 2401 | CMV | 62 | NA | −0.434 |
15751 | 2401 | CMV | 80 | NA | 0.049 |
14412 | 2715 | CMV | 125 | 38 | −1.1 |
14441 | 2718 | CMV | 43 | NA | 0.247 |
14465 | 2725 | CMV | 62 | 25 | −0.297 |
14575 | 2890 | CMV | 34 | 15 | −0.557 |
14642 | 3023 | CMV | 47 | NA | 0.190 |
14640 | 3023 | CMV | 54 | NA | −0.238 |
15278 | 3203 | CMV | 47 | 32 | −0.326 |
15488 | 3203 | CMV | 60 | 32 | −0.338 |
17182 | 3203 | CMV | 95 | 32 | 0.107 |
17183 | 3203 | CMV | 122 | 32 | −0.758 |
16629 | 3203 | CMV | 129 | 32 | −0.33 |
16630 | 3203 | CMV | 136 | 32 | −0.328 |
16628 | 3203 | CMV | 143 | 32 | −0.69 |
17184 | 3203 | CMV | 150 | 32 | −0.474 |
14753 | 3263 | CMV | −1 | 53 | 0.728 |
14751 | 3263 | CMV | 19 | 53 | 0.657 |
15452 | 3340 | CMV | 53 | 34 | 0.676 |
17149 | 2038 | EBV | 357 | NA | −0.133 |
15486 | 2250 | EBV | 303 | NA | −0.443 |
15718 | 2250 | EBV | 331 | NA | −0.724 |
14447 | 2719 | EBV | 120 | 48 | −1.266 |
17173 | 2890 | EBV | 248 | 15 | −0.887 |
15719 | 3049 | EBV | 159 | 29 | 0.555 |
17174 | 3049 | EBV | 166 | 29 | −0.009 |
17175 | 3049 | EBV | 173 | 29 | −0.034 |
16125 | 3049 | EBV | 179 | 29 | 0.319 |
17176 | 3049 | EBV | 186 | 29 | 0.365 |
16625 | 3049 | EBV | 200 | 29 | −0.044 |
17177 | 3049 | EBV | 214 | 29 | 0.056 |
14673 | 3052 | EBV | 32 | NA | −0.074 |
14687 | 3065 | EBV | 31 | 52 | 0.558 |
15450 | 3264 | EBV | 59 | NA | −0.763 |
16360 | 3264 | EBV | 94 | NA | −0.674 |
15490 | 3340 | EBV | 46 | 34 | 0.952 |
15721 | 3340 | EBV | 74 | 34 | −0.725 |
15787 | 3340 | EBV | 81 | 34 | −0.577 |
17186 | 3340 | EBV | 136 | 34 | −0.573 |
15491 | 3341 | EBV | 34 | NA | −0.3 |
Summary of the data of samples taken at the time of viral reactivation in our study set. SampleId, patientID, time of reactivation (days/HSCT), aGvHD development (if appropriate) in days, and the classification factor F are shown.
NA indicates not applicable (no GvHD developed); italic, false positive.